Tokio Marine Asset Management’s Idexx Laboratories IDXX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.3M | Sell |
4,360
-100
| -2% | -$56.1K | 0.07% | 230 |
|
|
2026
Q1 | $2.51M | Sell |
4,460
-57
| -1% | -$36.6K | 0.09% | 187 |
|
|
2025
Q4 | $3.06M | Sell |
4,517
-375
| -8% | -$255K | 0.11% | 146 |
|
|
2025
Q3 | $3.13M | Sell |
4,892
-767
| -14% | -$466K | 0.11% | 145 |
|
|
2025
Q2 | $3.04M | Sell |
5,659
-12,798
| -69% | -$6.12M | 0.12% | 144 |
|
|
2025
Q1 | $7.75M | Buy |
18,457
+3,829
| +26% | +$1.66M | 0.28% | 77 |
|
|
2024
Q4 | $6.05M | Buy |
14,628
+8,639
| +144% | +$3.79M | 0.21% | 98 |
|
|
2024
Q3 | $3.03M | Sell |
5,989
-93
| -2% | -$45.2K | 0.13% | 121 |
|
|
2024
Q2 | $2.96M | Sell |
6,082
-79
| -1% | -$39.7K | 0.14% | 113 |
|
|
2024
Q1 | $3.33M | Sell |
6,161
-703
| -10% | -$384K | 0.17% | 96 |
|
|
2023
Q4 | $3.81M | Sell |
6,864
-164
| -2% | -$77K | 0.21% | 77 |
|
|
2023
Q3 | $3.07M | Sell |
7,028
-596
| -8% | -$297K | 0.19% | 80 |
|
|
2023
Q2 | $3.83M | Sell |
7,624
-386
| -5% | -$185K | 0.24% | 69 |
|
|
2023
Q1 | $4.01M | Sell |
8,010
-2,676
| -25% | -$1.28M | 0.28% | 66 |
|
|
2022
Q4 | $4.36M | Sell |
10,686
-770
| -7% | -$299K | 0.34% | 66 |
|
|
2022
Q3 | $3.73M | Sell |
11,456
-275
| -2% | -$101K | 0.32% | 56 |
|
|
2022
Q2 | $4.11M | Buy |
11,731
+1,622
| +16% | +$661K | 0.36% | 50 |
|
|
2022
Q1 | $5.53M | Buy |
10,109
+2,593
| +34% | +$1.36M | 0.44% | 47 |
|
|
2021
Q4 | $4.95M | Buy |
7,516
+2,215
| +42% | +$1.39M | 0.39% | 45 |
|
|
2021
Q3 | $3.3M | Buy |
5,301
+2,123
| +67% | +$1.43M | 0.29% | 55 |
|
|
2021
Q2 | $2.01M | Buy |
3,178
+709
| +29% | +$391K | 0.18% | 70 |
|
|
2021
Q1 | $1.21M | Buy |
2,469
+869
| +54% | +$435K | 0.12% | 101 |
|
|
2020
Q4 | $800K | Buy |
1,600
+165
| +11% | +$73.8K | 0.09% | 127 |
|
|
2020
Q3 | $564K | Sell |
1,435
-255
| -15% | -$94.3K | 0.07% | 138 |
|
|
2020
Q2 | $558K | Sell |
1,690
-483
| -22% | -$140K | 0.08% | 123 |
|
|
2020
Q1 | $526K | Hold |
2,173
| – | – | 0.09% | 113 |
|
|
2019
Q4 | $567K | Buy |
2,173
+175
| +9% | +$46.1K | 0.09% | 127 |
|
|
2019
Q3 | $543K | Sell |
1,998
-175
| -8% | -$48.7K | 0.09% | 127 |
|
|
2019
Q2 | $598K | Sell |
2,173
-172
| -7% | -$42.4K | 0.1% | 121 |
|
|
2019
Q1 | $524K | Sell |
2,345
-279
| -11% | -$57.6K | 0.1% | 130 |
|
|
2018
Q4 | $488K | Sell |
2,624
-31
| -1% | -$6.36K | 0.1% | 133 |
|
|
2018
Q3 | $663K | Sell |
2,655
-545
| -17% | -$132K | 0.12% | 113 |
|
|
2018
Q2 | $697K | Sell |
3,200
-1,300
| -29% | -$268K | 0.13% | 116 |
|
|
2018
Q1 | $861K | Sell |
4,500
-1,000
| -18% | -$185K | 0.15% | 141 |
|
|
2017
Q4 | $860K | Buy |
5,500
+600
| +12% | +$94.4K | 0.13% | 162 |
|
|
2017
Q3 | $762K | Buy |
4,900
+2,000
| +69% | +$316K | 0.11% | 163 |
|
|
2017
Q2 | $468K | Buy |
+2,900
| New | +$471K | 0.07% | 223 |
|
Other funds holding IDXX
Tokio Marine Asset Management's IDXX Position: Q2 2026 in Review
Tokio Marine Asset Management reduced its Idexx Laboratories (IDXX) stake by 2.2% in Q2 2026, selling an estimated $56.1K and leaving 4,360 shares worth $2.3M. The position accounts for 0.07% of the portfolio, ranked #230.
Tokio Marine Asset Management first reported a position in IDXX in Q2 2017 and has held it in 37 quarters since. The position peaked at $7.75M in Q1 2025. 1,295 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.
- Tokio Marine Asset Management held 4,360 shares of Idexx Laboratories worth $2.3M as of Q2 2026.
- Tokio Marine Asset Management sold 100 Idexx Laboratories shares in Q2 2026, an estimated $56.1K.
- Idexx Laboratories made up 0.07% of Tokio Marine Asset Management's portfolio in Q2 2026, its #230 holding.
- Tokio Marine Asset Management first reported a position in Idexx Laboratories in Q2 2017 and has held it in 37 quarters since.
- Tokio Marine Asset Management's Idexx Laboratories position peaked at $7.75M in Q1 2025.
- 1,295 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.
Based on Tokio Marine Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.